Hi David, it's hard to tell from the way that the melanoma results are reported if it really worked or not. There appears to be a typo in the over 50 survival rates. Also, they compare responders to non-responders, but not to placebo. It may be that the reponders would have a better survival rate anyway because it indicates that their immunity is better anyway.
In any case, attaching a hapten to melanoma antigens could be a way of improving LMI. LMI attaches melanoma antigens to a cell-size sphere. It has been shown that in many cases, tumor immunity requires that antigens be presented a certain distance apart and at a specific angle to induce an immunological reponse by cytotoxic T-cells ( killer cells). (Luis, it does not kill t-cells).
Alliances include Yamanouche Europe, CTS in Israel, Boryung pharm. in Dorea, Grelan pharm. in Japan, and Brisol Myers Squibb. Lidak retains the rights for S America, China, Central America, Australia, India, and parts of the Far East. These agreements are for lidakol.
As far as management, they seem to finish their studies a little early and quickly progress to the next stage. As far as timing releases, in the long run it won't matter. I have also gotten the impression that they do not hype things, and have been accurate in what they say, especially when compared to many other biotech companies. This is a risky biotech stock with evidence that they may have something good going on that may pan out, maybe soon. |
